MAXIGRATAN 150 Capsules

A Novel Direct Thrombin inhibitor Par Excellence

 

COMPOSITION: Dabigatran Etexilate Mesilate eq. to Dabigatran Etexilate 150mg

  • Dabigatran etexilate mesylate is an outstanding anticoagulant, beneficial in the treatment of stroke and systemic embolism.
  • Effective in the treatment of deep vein thrombosis, pulmonary embolism and non-valvular atrial fibrillation.
  • Also used for the prevention of venous thromboembolic events in patients with recent elective hip or knee replacement surgery and atrial fibrillation.
  • Benefits of DES (Dabigatran Etexilate Mesylate) includes a fast onset and offset of action, a relatively short half-life and limited drug-drug interaction.
  • Demonstrates superiority over enoxaparin in treatment of venous embolism after orthopedic surgery.
  • Clinical trials have proven that it is more efficacious than warfarin and does not require any coagulation monitoring.
  • Also prevents and treats recurring blood clots in veins of legs and lungs.

INDICATIONS:

  • Stroke
  • Systemic embolism
  • Deep vein thrombosis
  • Pulmonary embolism
  • Recurrent pulmonary embolism
  • Non-valvular atrial fibrillation

 

 

Category:

Description

Dabigatran Etexilate

Drug class: Direct thrombin inhibitors

  • Benefits of DES (Dabigatran Etexilate Mesylate) include a fast onset and offset of action, a relatively short half-life, and limited drug-drug interaction.
  • Demonstrates superiority over enoxaparin in the treatment of venous embolism afteorthopedicic surgery.3
  • Clinical trials have proven that it is more efficacious than warfarin and does not require any coagulation monitoring.
  • Also prevents and treats recurring blood clots in veins of legs and lungs.
  • Dabigatran etexilate mesylate is an outstanding anticoagulant, beneficial in the treatment of stroke and systemic embolism.
  • Effective in the treatment of deep vein thrombosis, Pulmonary embolism, recurrent pulmonary embolism, and Non-valvular atrial fibrillation.’
  • Also used for the prevention of venous thromboembolic events in patients with recent elective hip or knee replacement surgery and atrial fibrillation.